Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in EGFR-mutant non-squamous NSCLC
NCT05184712Phase 3Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivonescimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Akeso, Inc. Primary endpoint: Progression-Free Survival at 2 years. Started Jan 2022; status: active, not recruiting.
02
Drugs
ivonescimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05184712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184712.